The Conversation (0)
Immuron (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, is pleased to announce its half year sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan. As quoted in the press release: Immuron Marketing Manager Mr David Montgomery, …
Immuron (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, is pleased to announce its half year sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan.
As quoted in the press release:
Immuron Marketing Manager Mr David Montgomery, said: “Key factors that have positively impacted the ongoing sales momentum include the continued focus on improving the execution of our trade marketing strategy in both the US and Australian markets. We are anticipating that the same sales trajectory will continue for Travelan® for the remainder of the 2018 financial year to target our aim of achieving in excess of AUD$2 million in annual sales for the first time”.